(Q36578184)

15 August 2017

1 reference

title

Update on pathogen reduction technology for therapeutic plasma: an overview (English)

1 reference

15 August 2017

Solheim BG

1

1 reference

PubMed ID

16934528

15 August 2017

Seghatchian J

series ordinal

2

1 reference

15 August 2017

24 August 2006

1 reference

Transfusion and Apheresis Science

15 August 2017

1 reference

15 August 2017

35

1 reference

15 August 2017

1

1 reference

15 August 2017

83-90

1 reference

What is happening? Are the current acceptance criteria for therapeutic plasma adequate?

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Strategies for transfusion therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Solvent/detergent-treated plasma: composition, efficacy, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

What's happening? The quality of methylene blue treated FFP and cryo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Photodynamic virus inactivation of blood components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Preclinical safety profile of plasma prepared using the INTERCEPT Blood System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Viral safety of solvent/detergent-treated plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Composition, efficacy, and safety of S/D-treated plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Comparison of Solvent/Detergent-Inactivated Plasma and Fresh Frozen Plasma under Routine Clinical Conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

The Canadian apheresis registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

α2-Plasmin inhibitor is among acute phase reactants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Fibrinolysis during liver transplant and use of solvent/detergent virus-inactivated plasma (ESDEP/Octaplas).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Update of cost-effectiveness analysis for solvent-detergent-treated plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.02.004

10.1016/J.TRANSCI.2006.02.004

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16934528